Highest-materiality recent filing
Edesa Biotech shareholders approve equity plan amendment adding 750K shares
Shareholders approved Plan Amendment increasing shares available for issuance by 750,000 and eliminating annual per participant option grant limit.
Edesa Biotech CEO to receive 90% of salary as RSUs, up from 50%
CEO Pardeep Nijhawan will receive 90% of monthly base salary as fully vested RSUs, effective May 13, 2026.
Edesa Biotech Q2 net loss widens to $4.2M; progresses EB06 vitiligo Phase 2 prep
Net loss of $4.2M ($0.49/sh) for Q2 FY2026 vs $1.6M ($0.30/sh) in prior year.
Paridiprubart reduced adjusted 28-day mortality to 24% from 33% (27% relative risk reduction; p<0.001) in full 278-patient population.
Edesa Biotech Q1 FY2026 net loss $2.2M; progresses EB06 vitiligo Phase 2 prep
Net loss of $2.2M ($0.28/share) vs. $1.6M ($0.48/share) a year ago; operating expenses $2.3M.
Edesa reports FY2025 net loss $7.2M; Phase 3 paridiprubart meets endpoints
Net loss $7.2M ($1.27/share) vs $6.2M ($1.93/share) prior year; OpEx $7.9M.
Edesa Biotech increases ATM offering capacity to $2.26M; discloses prior sales of $3.72M
Prospectus supplement filed to increase max aggregate offering under ATM to $2,262,508.
Paridiprubart + SOC reduced 28-day mortality to 39% vs 52% placebo (n=104; p<0.001): 13% absolute improvement, 25% relative risk reduction.
Project completion extended to December 31, 2028 (from December 31, 2025); agreement expiration extended to later of Dec 2045 or last repayment.
Edesa Biotech files prospectus supplement for up to $4.0M ATM offering through H.C. Wainwright
ATM offering for up to $4,006,544 of common shares through H.C. Wainwright.
Edesa Biotech reports Q3 net loss of $1.7M; advances EB06 manufacturing for vitiligo Phase 2
Net loss of $1.7M ($0.25/sh) for quarter ended June 30, 2025, unchanged from $1.7M ($0.52/sh) YoY.
Edesa Biotech shareholders approve 1.725M share increase to 2019 equity plan
Shareholders approved amendment to 2019 Equity Incentive Compensation Plan increasing share reserve by 1,725,000 shares.
Edesa Biotech reports Q2 net loss of $1.6M; advances vitiligo drug EB06 to Phase 2
Net loss of $1.6M ($0.30/share) vs $1.9M ($0.58) in prior-year Q2; operating expenses fell to $1.6M.
Edesa Biotech appoints Peter Weiler as CFO effective May 1, 2025, replacing Stephen Lemieux
Stephen Lemieux resigns as CFO effective May 1, 2025, to pursue other opportunities; will continue as a senior financial advisor under a consulting agreement.
Edesa Biotech reports Q1 FY2025 net loss of $1.6M; raises $15M in private placement
Net loss of $1.6M ($0.48/share) compared to $1.7M ($0.54/share) in prior year quarter.
Edesa Biotech announces $15M private placement led by Velan Capital; appoints David Liu to board
Gross proceeds of $15M from sale of Series B-1 convertible preferred shares ($10K each) and 3.47M common shares at $1.92/share.
Edesa Biotech FY2024 net loss $6.2M ($1.93/sh); cash $1.0M, negative working capital
Net loss $6.2M ($1.93/sh) vs $8.4M ($2.93/sh) prior year; operating expenses down 24% to $7.0M.
Edesa Biotech enters $5M securities purchase agreement with CEO; $1.54M immediate investment
CEO-affiliated entity invests $1,540,819 for 150 Series A-1 Preferred Shares ($10K stated value) and warrants at $3.445 conversion/exercise price.
Entered ATM agreement with H.C. Wainwright to sell up to $3.87M common shares at market prices; commission 3%.
Edesa Biotech reports Q3 net loss $1.7M; ARDS drug selected for U.S. government study
Net loss of $1.7M ($0.52/shr) vs $2.0M ($0.68/shr) a year ago; nine-month loss $5.2M ($1.64/shr).
BARDA selects Edesa's paridiprubart for U.S. government-funded Phase 2 ARDS trial
Paridiprubart (EB05) chosen by BARDA for a randomized, double-blind, placebo-controlled Phase 2 platform trial in all-cause ARDS.
Edesa Biotech shareholders approve 67,000-share increase to equity plan, re-elect all directors
All seven director nominees elected with ~818-819 thousand votes for each; 654k broker non-votes.
Edesa Biotech Q2 FY2024 net loss $1.9M ($0.58/shr); advances ARDS Phase 3 and vitiligo study
Net loss narrowed to $1.9M vs $2.3M YoY; six-month loss $3.5M ($1.12/shr).
the Company appointed Peter J. Weiler to serve as the Company’s Chief Financial Officer, effective May 1, 2025
Stephen Lemieux, Chief Financial Officer of Edesa Biotech, Inc. (the “Company”), notified the Company of his intention to resign from his position and responsibilities as Chief Financial Officer, effective May 1, 2025, to pursue another professional opportunity.
the Company appointed David Liu, the Lead Investor Nominee, to serve on the Board of Directors
Max materiality 0.85 · Median 0.60 · Most common event other_material